The recent FDA approval of Motiva‘s SmoothSilk implants for breast augmentation in the U.S. marks a significant development in the field of aesthetic surgery. Hailing as the number one implant in Asia, let’s dive into Motiva’s claims as well as the research, giving you a balanced perspective on this brand new “luxury” implant. 

SmoothSilk’s Selling Points 

  • Reduced Inflammation: The implant’s patented SmoothSilk surface is touted to minimize inflammation, a key factor in capsular contracture, a complication where scar tissue tightens around the implant. This theoretically translates to lower capsular contracture rates, a significant benefit for patients. 
  • Ergonomic Design: The Motiva Ergonomix implant boasts a unique shape that adapts to body position, mimicking natural breast movement. This innovation could address a common patient complaint about unnatural appearance and feel associated with traditional implants. 
  • Safety and Efficacy: Establishment Labs cites a rigorous clinical trial demonstrating low complication rates, including capsular contracture (0.5%) and rupture (0.6%). These are encouraging numbers, but it’s important to consider the context. 
  • Extensive Experience: With nearly four million Motiva implants delivered globally, the company emphasizes its established track record. This experience suggests a certain level of quality and manufacturing expertise. 

Beyond the Hype 

While the specs paint a rosy picture, a closer examination reveals some nuances: 

  • Limited Data: The referenced clinical trial, though rigorous, has a three-year follow-up period. Long-term data is crucial for a definitive assessment of safety and efficacy. Particularly with capsular contracture, which can develop years after implantation, a longer follow-up period is necessary to draw more definitive conclusions about Motiva SmoothSilk’s impact on this complication. 
  • Newer Doesn’t Always Mean Better: The meta-analysis by Aitzetmüller-Klietz et al. (2023) analyzing existing studies on Motiva implants highlights the need for more robust research. While the meta-analysis suggests promising results for capsular contracture rates, the overall quality of the studies analyzed was just moderate. More high-quality studies are needed to confirm these findings. 
  • “Luxury” Often Comes at a Price: Cost may be a factor for patients. As with any new technology, Motiva SmoothSilk is likely to carry a premium price tag. This could limit access for some patients and potentially impact your practice’s affordability profile. 

Should Aesthetic Surgeons Invest in Motiva? 

The answer, as always, depends on your individual practice and patients. Here are some key takeaways for this promising technology: 

  • Promising Technology: Motiva SmoothSilk’s design and early data suggest it could be a valuable addition to your implant options. The potential for reduced inflammation, improved aesthetic outcomes with the ergonomic design, and low complication rates based on initial studies are all positive indicators. 
  • The Need for Long-Term Data: Encourage patients to understand that long-term safety and efficacy data are still emerging. Be transparent about the limitations of the current data and emphasize the importance of choosing an implant with a proven track record for some patients, especially those who may be more risk-averse. 
  • Informed Patient Discussion: Open communication with patients about the benefits, limitations, and costs of Motiva SmoothSilk compared to other implant options is crucial. Discuss their individual goals, risk tolerance, and budget to arrive at the most suitable implant choice. 

Motiva SmoothSilk represents a step forward in breast implant technology. The potential for reduced complications and improved aesthetics is certainly exciting. Additionally, the inclusion of new RFID technology holds exciting promise for clinical use. However, long-term data and further research are necessary to fully understand its place in the landscape of aesthetic surgery. By staying informed and engaging in open communication with patients, you can ensure well-considered decisions for optimal outcomes. 

Additional Points to Consider

  • How will the “ergonomic design” of the Motiva Ergonomix translate into patient satisfaction in terms of feel and appearance? While the design mimics natural breast movement, real-world patient experience will be crucial in understanding how this translates to long-term comfort and aesthetics. 
  • Will the “luxury” pricing of Motiva SmoothSilk limit patient access? The affordability of this new implant could be a significant factor for some practices. Understanding the cost structure and potential impact on your patient base is important. 
  • Are there any specific patient profiles that might benefit most from Motiva SmoothSilk implants? Certain patients may be more receptive to the potential benefits of Motiva SmoothSilk, such as those seeking a more natural look and feel or those with a history of capsular contracture. Identifying these ideal patient profiles can help you optimize treatment recommendations. 

By keeping these questions in mind and staying informed about the latest research and clinical experiences, you can make informed decisions about incorporating Motiva SmoothSilk implants into your practice and offering your patients the best possible options for breast augmentation. 

SOURCES: The Beauty Scientists Podcast, Motiva, Establishment Labs, Journal of Clinical Medicine 

RELATED ARTICLESMORE FROM AUTHOR